<DOC>
	<DOCNO>NCT00345696</DOCNO>
	<brief_summary>The purpose study determinate progression free survival 9 month treatment .</brief_summary>
	<brief_title>1stline Study Capecitabine Administered Continuous Way Plus Oxaliplatin &amp; Bevacizumab Every 2weeks Metastatic CCR .</brief_title>
	<detailed_description>To look new chemotherapy management get less acute chronic toxicity and/or easy administration treatment line . This study try demonstrate alternative chemotherapy scheme , continuous polychemotherapy regimen less dose added effect monoclonal antibody Bevacizumab .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Men woman &gt; = 18 year Outpatients ECOG performance status ≤ 2 . Histologically confirm diagnosis CRC patient metastasis . Presence least one detectable lesion accordance RECIST criterion . Life expectancy great 3 month . Patients able understand study request want participate . Written informed consent give Patients treat Bevacizumab previously . Received systemic treatment previously treat advanced metastatic disease Adjuvant neoadjuvant treatment nonmetastatic disease allow , provide finish least 6 month initial study treatment . If patient treat adjuvant therapy previously , allow include study case disease progression treatment 6 month later end treatment . If radiotherapy administer administered lesion select study , end treatment finish least 4 week study initiation . Previous surgical procedure IV stage disease allow . PAst current history ( within last 5 year ) malignancy except curatively treat basal squamous cell carcinoma skin , insitu carcinoma cervix . History evidence upon physical examination central nervous system ( CNS ) ( i.e . primary cerebral tumour , uncontrolled convulsion standard medical treatment , cerebral metastasis kind ictus history ) . History psychiatric disability judge investigator clinically significant precluding inform consent interfere compliance oral drug intake . Clinically significant cardiovascular disease ( active ) , i.e , uncontrolled hypertension , unstable angina , New York Heart Association ( NYHA ) grade II great congestive heart failure , serious cardiac arrhythmia require medication peripheral vascular disease . Patients undergone myocardial infarction previous year study initiation exclude . Lack physical integrity upper gastrointestinal tract , malabsorption syndrome inability take oral medication Patients subject allogenic transplant request immunotherapy . Bone fracture heal , wound severe ulcer . Known hemorrhagic diathesis coagulopathy . Uncontrolled severe intercurrent infection another severe uncontrolled concomitant disease . Moderate severe renal impairment ( creatinine clearance &lt; 30 ml/min ( calculate accord CockroftGault formula ) serum creatinine &gt; 1,5 x ULN . Any follow laboratory value : Absolute neutrophils count ( ANC ) &lt; 1.5 x 109/l . Platelet count &lt; 100 x 109/l . Hemoglobin &lt; 9 g/dl . INR &gt; 1.5 . Total bilirubin &gt; 1.5 ULN . ALT and/or AST &gt; 2.5 x ULN &gt; 5 x ULN ( case hepatic metastasis ) . Alkaline phosphatase &gt; 2.5 x ULN &gt; 5 x ULN ( case hepatic metastasis ) , &gt; 10 x ULN ( case bone metastasis ) . History unexpected serious adverse event fluoropyrimidine treatment know dihydropyrimidine dehydrogenase ( DPD ) deficiency . Patients subject major surgical procedure , open biopsy significant traumatic injures 28 day time start study treatment , patient major surgery procedure planning study period . Fine needle aspiration biopsy 7 day study initiation . Use full dose oral parenteral anticoagulant ( least 10 day start study treatment thrombolytic agent . Low dose warfarin allow , INR ≤ 1.5 . Subject require chronic use high dose aspirin ( &gt; 325 m/day ) nonsteroidal antiinflammatory treatment . Participation another treatment trial within 4 week study initiation . Pregnant ( serum positive pregnancy test ) lactate woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Bevacizumab</keyword>
	<keyword>First line</keyword>
</DOC>